Indian Court Hands Novartis Setback In Gleevec Patent Case

This article was originally published in PharmAsia News

07 Aug 2007
News

PharmAsia News @PharmAsiaNews pharmasia@informa.com

Executive Summary

Novartis suffered a major blow Aug. 6 when an Indian court dismissed its challenge of a key government provision that blocks the company from obtaining a patent for its oncologic Gleevec (imatinib)

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC066494

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC066494

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Indian Court Hands Novartis Setback In Gleevec Patent Case

News

Executive Summary

Related Content

IP Protection Concerns Grow In India, PhRMA Says

IP Protection Concerns Grow In India, PhRMA Says

Lost In Bureaucracy? Novartis Gleevec IP Case Held Up By Indian Legal System

Intellectual Property In India: Novartis Gleevec Suit Is First Challenge To Law Restricting New Formulation Patents (Part 2 of 3)

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert